Want to see JP:4891 full AI Analyst Report?
4891 Stock Chart & Stats
¥129.00
-¥1.00(-0.47%)
At close: 4:00 PM EST
¥129.00
-¥1.00(-0.47%)
Day’s Range― - ―
52-Week Range¥99.00 - ¥185.00
Previous CloseN/A
Volume100.70K
Average Volume (3M)256.91K
Market Cap
¥4.98B
Enterprise Value¥2.56B
Total Cash (Recent Filing)¥3.18B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.99
Shares Outstanding45,664,467
10 Day Avg. Volume257,770
30 Day Avg. Volume256,913
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)2.07
Price to Sales (P/S)0.00
P/FCF Ratio-7.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-25.28
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetA debt-free, conservatively financed balance sheet materially lowers structural financial risk and interest burden. Over 2-6 months this provides flexibility to prioritize R&D or strategic options, reduces default risk, and improves ability to raise non-debt financing without near-term covenant pressure.
Demonstrated Cash-generation YearA materially cash-positive 2022 demonstrates the company can generate operating cash when commercial activity scales. This historical precedent shows a feasible pathway to restore self-funded operations if revenue-producing activities resume, making recovery more credible than for firms with no cash-positive history.
Lean Cost BaseA very small headcount implies a low fixed-cost structure that extends runway and reduces incremental financing needs. In biotech this allows focused R&D or partnering efforts with lower burn, improving survivability during multi-quarter commercialization or development cycles.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow across multiple years signals structural funding risk. Over months this erodes available liquidity, forces reliance on external financing or asset sales, and constrains investment in clinical or commercial activities, undermining long-term viability without corrective action.
Absent Recurring RevenueThe lack of recurring commercial revenue removes predictable cash inflows necessary to sustain operations. This structural weakness increases dependency on financing rounds or milestone-based receipts, making forecasting, margin improvement, and long-term scaling uncertain absent durable revenue recovery.
Eroding Equity BaseDeclining shareholders' equity from multi-year losses weakens the balance sheet cushion and reduces flexibility to absorb further losses. Over a 2-6 month horizon this may limit borrowing capacity or attract more dilutive financing, complicating partnerships and long-term R&D investment plans.
TMS Co., Ltd. News
4891 FAQ
What was TMS Co., Ltd.’s price range in the past 12 months?
TMS Co., Ltd. lowest stock price was ¥99.00 and its highest was ¥185.00 in the past 12 months.
What is TMS Co., Ltd.’s market cap?
TMS Co., Ltd.’s market cap is ¥4.98B.
When is TMS Co., Ltd.’s upcoming earnings report date?
TMS Co., Ltd.’s upcoming earnings report date is Aug 14, 2026 which is in 41 days.
How were TMS Co., Ltd.’s earnings last quarter?
TMS Co., Ltd. released its earnings results on May 15, 2026. The company reported -¥4.49 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.49.
Is TMS Co., Ltd. overvalued?
According to Wall Street analysts TMS Co., Ltd.’s price is currently Overvalued.
Does TMS Co., Ltd. pay dividends?
TMS Co., Ltd. does not currently pay dividends.
What is TMS Co., Ltd.’s EPS estimate?
TMS Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TMS Co., Ltd. have?
TMS Co., Ltd. has 45,664,467 shares outstanding.
What happened to TMS Co., Ltd.’s price movement after its last earnings report?
TMS Co., Ltd. reported an EPS of -¥4.49 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of TMS Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4891
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TMS Co., Ltd.
Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceuticals, quasi-drugs, drug substances, medical devices, and various medical commodities. The company's pipeline includes TMS-007, an SMTP congener demonstrating both prothrombolytic and anti-inflammatory/antioxidative activities, which has advanced through Phase 2a clinical trials for the treatment of acute ischemic stroke. Additionally, TMS-008, another SMTP congener with anti-inflammatory/antioxidative properties, is undergoing nonclinical development for addressing inflammatory complications like acute kidney injury and cancer cachexia. A third product candidate, TMS-009, is currently in preclinical development. TMS Co., Ltd. collaborates with Hokkaido University and Kanazawa University to assess the potential of its drug candidates, has a joint research agreement with Teikyo University to identify renal function biomarkers, and maintains a strategic alliance with Ji Xing Pharmaceuticals Limited.